2800 Woodlawn Drive, Suite 129
Cardax is focusing first on developing products utilizing astaxanthin, a naturally occurring compound demonstrated to reduce inflammation, at its source, without the harmful side effects of current anti-inflammatory treatments (e.g., steroids and NSAIDs).
Astaxanthin use is supported by hundreds of peer-reviewed papers published in leading medical research journals. More than 40 human clinical trials supporting the safety and efficacy of astaxanthin have been conducted to date. As the broader scientific community has discovered the health benefits of astaxanthin, awareness and demand for astaxanthin has grown dramatically.
We expect astaxanthin to address underserved multi-billion dollar chronic disease markets, including areas such as osteoarthritis, cognitive decline, metabolic syndrome, dyslipidemia, diabetes, liver disease, and cardiovascular disease.
Cardax has strategic alliances with BASF, related to the proprietary, scalable, and cost-effective manufacture of nature-identical astaxanthin, and Capsugel, related to the proprietary formulation of astaxanthin for increased oral bioavailability. These strategic alliances provide near-term revenue potential from consumer health applications. Cardax may also pursue pharmaceutical applications.
Cardax management and Board have strong operational and technical expertise in healthcare product development and astaxanthin manufacturing and science.
Our patents protect compositions of matter, pharmaceutical compositions, and pharmaceutical uses of astaxanthin and related products in key disease areas.
The safety and efficacy of our product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.
CEO: David G. Watumull
CSO: Gilbert Rishton, PhD
CFO: John Russell